Tolerability of inhaled, humidified air at two temperatures (41 and 45 degrees Celsius) in healthy participants

Not Applicable

Completed

• Conditions: pper Respiratory Tract Infection; Upper Respiratory Tract Infection; Respiratory - Other respiratory disorders / diseases; Infection - Other infectious diseases

• Registration Number: ACTRN12621000853842
• Lead Sponsor: Fisher & Paykel Healthcare Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-07-02
• Study Completion: 2022-06-17
• Last Update Posted: 28 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Twenty healthy participants aged 18 to 75 years who are in the Investigator’s opinion, able and willing to comply with all study requirements.
Two weeks post full vaccination against SARS-CoV-2 (COVID-19); may either be New Zealand based COMINARTY (Pfizer BioNTech) or administration of equivalent vaccination

Exclusion Criteria

Upper respiratory tract infection (sore throat, cough, rhinorrhoea and/or fever (subjective of objective) within the last fourteen days

Chronic respiratory illness currently being treated e.g. asthma

Nasopharyngeal conditions such as a deviated septum and acute/chronic rhinitis, which the investigator considers could impair nasal breathing

Use of nasal sprays within the last seven days

Current smoker, defined as someone who has smoked or vaped within the last 28 days

Current use of or requirement of oral antibiotics for a respiratory tract infection, pneumonia or infective exacerbation of an underlying respiratory condition

Current use of or requirement of parenteral antibiotics

Have an implantable medical device

Have any other condition which, at the investigator’s discretion, is believed may present a safety risk to the participant or others, or impact the study results or the feasibility of the study.

Previous enrolment in any trials investigating the use of rhinothermy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of participants in each intervention/comparator group who could not tolerate rNHF for sixty minutes, as determined by review of the study database for the number of participants who stopped treatment prior to sixty minutes[Up to 60 minutes post commencement of intervention (Time 0)]